Drug–drug interactions with cannabidiol (CBD) appear to have no effect on treatment response in an open-label Expanded Access Program
@article{Gaston2019DrugdrugIW, title={Drug–drug interactions with cannabidiol (CBD) appear to have no effect on treatment response in an open-label Expanded Access Program}, author={Tyler E. Gaston and E. Martina Bebin and Gary R. Cutter and Steve B. Ampah and Yuliang Liu and Leslie P. Grayson and Jerzy P. Szaflarski}, journal={Epilepsy \& Behavior}, year={2019}, volume={98}, pages={201-206} }
27 Citations
Does cannabidiol have antiseizure activity independent of its interactions with clobazam? An appraisal of the evidence from randomized controlled trials
- MedicineEpilepsia
- 2020
The best clinical evidence to date is provided that CBD exerts therapeutic effects in patients with epilepsy that are independent of its interaction with CLB, and greater antiseizure effects, and a greater burden of adverse effects, are observed when CBD is combined withCLB.
Efficacy of cannabidiol in subjects with refractory epilepsy relative to concomitant use of clobazam
- MedicineEpilepsy Research
- 2020
Long-term safety and efficacy of highly purified cannabidiol for treatment refractory epilepsy
- MedicineEpilepsy & Behavior
- 2021
Cannabinoids in the Treatment of Epilepsy: Current Status and Future Prospects
- Biology, MedicineNeuropsychiatric disease and treatment
- 2020
Most patients reported adverse events (AEs), generally from mild to moderate and transient, which mainly consisted of somnolence, sedation, decreased appetite, diarrhea and elevation in aminotransferase levels, the last being documented only in subjects on concomitant valproate therapy.
Clinical trial simulations of the interaction between cannabidiol and clobazam and effect on drop-seizure frequency.
- Medicine, PsychologyBritish journal of clinical pharmacology
- 2019
The results show that the effect of cannabidiol on the median reduction in drop-seizure frequency in patients with Lennox-Gastaut syndrome may be explained by a drug-drug interaction with clobazam.
Cannabidiol Interactions with Medications, Illicit Substances, and Alcohol: a Comprehensive Review
- MedicineJournal of General Internal Medicine
- 2021
Cannabidiol has been reported to interact with anti-epileptic drugs, antidepressants, opioid analgesics, and THC, but surprisingly, it interacts with several other common medications, e.g. acetaminophen, and substances including alcohol.
An update on drug interaction considerations in the therapeutic use of carbonic anhydrase inhibitors
- Medicine, ChemistryExpert opinion on drug metabolism & toxicology
- 2020
Carbonic anhydrase inhibitors have been in clinical use for decades for the management of various disorders but also for better controlling some diseases, such as hypoxic tumors, case for which the combination of CAIs with other anticancer agents proved to be synergistic.
Reduced efficacy and risk of seizure aggravation when cannabidiol is used without clobazam
- BiologyEpilepsy & Behavior
- 2020
Pharmacogenetic Predictors of Cannabidiol Response and Tolerability in Treatment‐Resistant Epilepsy
- Biology, MedicineClinical pharmacology and therapeutics
- 2021
Pharmacogenetic variation is associated with CBD response and influences expression of CBD targets in TRE and Implicated pathways, including cholesterol metabolism and glutathione conjugation, demonstrate potential interactions between CBD and common medications that may require closer monitoring.
Highly Purified Cannabidiol for Epilepsy Treatment: A Systematic Review of Epileptic Conditions Beyond Dravet Syndrome and Lennox–Gastaut Syndrome
- Medicine, PsychologyCNS Drugs
- 2021
The currently available data suggest that response to treatment with a highly purified, plant-derived CBD oil-based solution can be seen in patients across a broad range of epilepsy disorders and etiologies, and can provide preliminary support for additional research.
References
SHOWING 1-10 OF 27 REFERENCES
Higher cannabidiol plasma levels are associated with better seizure response following treatment with a pharmaceutical grade cannabidiol
- MedicineEpilepsy & Behavior
- 2019
Cannabidiol improves frequency and severity of seizures and reduces adverse events in an open-label add-on prospective study
- MedicineEpilepsy & Behavior
- 2018
Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome
- MedicineNeurology
- 2018
This study provides Class I evidence that for children with Dravet syndrome, CBD resulted in more AEs than placebo but was generally well-tolerated.
Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial
- Medicine, PsychologyThe Lancet Neurology
- 2016
Anticonvulsant effects of cannabinoids in mice: Drug interactions within cannabinoids and cannabinoid interactions with phenytoin
- Biology, MedicinePsychopharmacologia
- 2004
The administration of δ9-THC significantly potentiated the anticonvulsant effectiveness of phenytoin against electroshock seizures and this effect was further potentiated by the concurrent administration of CBD.
Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial
- Medicine, PsychologyThe Lancet
- 2018
Clobazam Therapeutic Drug Monitoring: A Comprehensive Review of the Literature With Proposals to Improve Future Studies
- MedicineTherapeutic drug monitoring
- 2013
Future clobazam TDM studies need to use trough concentrations after steady state has been reached and standardization and more studies of C/D ratios from clobzam and other drugs can be helpful to move TDM forward.
Effect of Cannabidiol on Drop Seizures in the Lennox–Gastaut Syndrome
- Medicine, PsychologyThe New England journal of medicine
- 2018
Among children and adults with the Lennox–Gastaut syndrome, the addition of cannabidiol at a dose of 10 mg or 20 mg per kilogram per day to a conventional antiepileptic regimen resulted in greater reductions in the frequency of drop seizures than placebo.
Drug–drug interaction between clobazam and cannabidiol in children with refractory epilepsy
- Medicine, PsychologyEpilepsia
- 2015
Under an expanded access investigational new drug (IND) trial, cannabidiol (CBD) is being studied as a possible adjuvant treatment of refractory epilepsy in children, and it is predicted a drug–drug interaction.